Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

367 Features
Increasing numbers of people are suffering from Asthma

31 Mar 08

Asthma is a significant health problem. Acording to the National Asthma Campaign, the condition continues to grow, and in the UK an estimated 8 million people are diagnosed as having asthma, with 5 million people receiving treatment. The cost of asthma to the NHS is more than £850 million a year.
Mike Wood

Bell Pottinger EXPANDS healthcare business

25 Mar 08

Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort.
Deborah Cockerill

Research could put penicillin back in battle against antibiotic resistant bugs that kill millions

12 Mar 08

Research led by the University of Warwick has uncovered exactly how the bacterium Streptococcus pneumoniae has become resistant to the antibiotic penicillin. The same research could also open up MRSA to attack by penicillin and help create a library of designer antibiotics to use against a range of other dangerous bacteria.
Editor

Roche to announce new breast cancer data

11 Dec 07

Roche to announce new breast cancer data pointing to better survival chances and potential for cure Phase II results suggest Avastin can be used in curative setting
Anne Cameron

Almirall reveals leading edge inhaler for new COPD drug aclidinium bromide

04 Dec 07

Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication.
Olwen Glynn Owen - Pharmiweb Field Reporter

PharmiWeb Solutions is expanding

28 Nov 07

Are you keen to join a young, entrepreneurial, fast growth organisation? We'd like to hear from you.
Colin Williams

Pharma ROI – RIP or SOP?

27 Nov 07

PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here.
Editor

Franchising & Novou-Consumerism in Middle East

25 Sep 07

Two things; firstly among all of the great business concepts of the last few decades the franchise model has always surfaced to the very top. Secondly, over the next decade the introduction of hundreds of fresh, locally nurtured franchise concepts emerging within Dubai and the Gulf States will set the stage for a great revolution of nouvo-consumerism. So what are the four key factors driving this movement?
Naseem Javed

PharmiWeb Solutions shortlisted for the Best Online Publisher awards

06 Sep 07

Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award.
Colin Williams

BIPOLAR DISORDER: a new holistic approach

30 Jul 07

BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects
Olwen Glynn Owen

Wyeth Reports Earnings Results for the 2007 Second Quarter and First Half

25 Jul 07

Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half.
Douglas Petkus

Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager

02 Jul 07

Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings
Dan Barrington

Erbitux moves to front-line in attack against both metastatic head and neck and colorectal cancers

11 Jun 07

The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first
Olwen Glynn Owen

Sponsor a CEO

11 Jun 07

Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra).
Editor

CRYSTAL trial reveals benefits of first-line cetuximab in mCRC

08 Jun 07

Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium.
Olwen Glynn Owen

Lhasa Acts in Support of Science Education in Africa

05 Jun 07

In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference.
Lhasa Limited

BENEFiT study shows Tracleer (bosentan) improves haemodynamics in CTEPH patients refused surgery

04 Jun 07

Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition.
Olwen Glynn Owen

So you want to contract staff… what do you need to consider?

23 May 07

In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market.
Paula Mumby

What’s Up (Junior) Doc?

22 May 07

With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was
Paul Hartigan

The Newspaper Cemetery

14 May 07

Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket.
Naseem Javed

Questioning whether age discrimination affects pharma recruitment

10 May 07

Its hard gaining entry into the pharmaceutical industry, but is it harder if you are thirty? I’m a graduate, so I can get in like a graduate, can’t I?
Toni Gardner

Europeans in the ‘twilight zone’ of type 2 diabetes care are living under a false sense of security and set to suffer avoidable long-term consequences

23 Apr 07

The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care.
Gaja Pellegrini-Bettoli

Wyeth’s Winning Ways: Big Pharma Bounces Back

20 Apr 07

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
Paul Hartigan

A Gala Tribute to Global Copycats

03 Apr 07

Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards?
Naseem Javed

Global Image Re-Positioning 2007

30 Jan 07

Suddenly, there is a new global tidal wave of change all over the Asian region, the obvious signs are people on the move, new developments and properties popping up all over the region and a nouvo-consumerism is appearing at every corner, customers are buying shiny and wonderful things with beautiful packaging and companies are addressing their hunger with massive blitzes. ...
Naseem Javed

Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy

30 Jan 07

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Olwen Glynn Owen

The iPhones, iPains & iProblems

16 Jan 07

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
Naseem Javed

Eltrombopag (Promacta) offers hope of an effective oral treatment for bleeding due to thrombocytopenia

03 Jan 07

Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III
Olwen Glynn Owen

Pharma turns to reformulation to maximize ROI

15 Dec 06

With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
Datamonitor

AstraZeneca has announced that it will launch a generic version of its own heart drug Toprol XL.

24 Nov 06

AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.